http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 07:50:44 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Maxim+Group+Starts+Filana+Therapeutics+%28FLNA%29+at+Buy/26546027.html <p>Maxim Group analyst Jason M initiates coverage on Filana Therapeutics (NASDAQ: FLNA) with a Buy rating and a price target of $5.00.</p> <p>For an analyst ratings summary and ratings history on Filana Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=FLNA">click here</a>. For more ratings news on Filana Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FLNA&amp;type=analyst">click here</a>.</p> <p>Shares of Filana Therapeutics closed at $1.31 yesterday.</p> http://www.streetinsider.com/New+Coverage/Maxim+Group+Starts+Filana+Therapeutics+%28FLNA%29+at+Buy/26546027.html Tue, 26 May 2026 07:50:44 -0400 FLNA http://www.streetinsider.com/Hot+New+Coverage/Maxim+Group+Starts+Filana+Therapeutics+%28FLNA%29+at+Buy/26546027.html <p>Maxim Group analyst Jason M initiates coverage on Filana Therapeutics (NASDAQ: FLNA) with a Buy rating and a price target of $5.00.</p> <p>For an analyst ratings summary and ratings history on Filana Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=FLNA">click here</a>. For more ratings news on Filana Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FLNA&amp;type=analyst">click here</a>.</p> <p>Shares of Filana Therapeutics closed at $1.31 yesterday.</p> http://www.streetinsider.com/Hot+New+Coverage/Maxim+Group+Starts+Filana+Therapeutics+%28FLNA%29+at+Buy/26546027.html Tue, 26 May 2026 07:50:44 -0400 FLNA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html si-local-file:///var/storage/secattach/20260507/26455237.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html Thu, 07 May 2026 17:16:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html si-local-file:///var/storage/secattach/20260507/26455237.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html Thu, 07 May 2026 17:16:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html si-local-file:///var/storage/secattach/20260507/26455237.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++FILANA+THERAPEUTICS%2C++++++For%3A+Mar+31/26455237.html Thu, 07 May 2026 17:16:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html si-local-file:///var/storage/secattach/20260507/26448955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html Thu, 07 May 2026 08:10:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html si-local-file:///var/storage/secattach/20260507/26448955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html Thu, 07 May 2026 08:10:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html si-local-file:///var/storage/secattach/20260507/26448955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FILANA+THERAPEUTICS%2C++++++For%3A+May+07/26448955.html Thu, 07 May 2026 08:10:00 -0400 FLNA O.00073827 SAVA http://www.streetinsider.com/Earnings/Filana+Therapeutics%2C+Inc.+%28FLNA%29+Tops+Q1+EPS+by+10c/26448853.html <p>Filana Therapeutics, Inc. (NASDAQ: FLNA) reported Q1 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31).</p><p>For earnings history and earnings-related data on Filana Therapeutics, Inc. (FLNA) <a href="http://www.streetinsider.com/ec_earnings.php?q=FLNA">click here</a>.</p> http://www.streetinsider.com/Earnings/Filana+Therapeutics%2C+Inc.+%28FLNA%29+Tops+Q1+EPS+by+10c/26448853.html Thu, 07 May 2026 08:04:50 -0400 FLNA http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html <p align="justify">AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.</p> <p align="justify">“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options http://www.streetinsider.com/Globe+Newswire/Filana+Therapeutics+Reports+Q1+2026+Financial+Results+and+Business+Update/26448738.html Thu, 07 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html <p align="justify">AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company’s clinical development program evaluating simufilam in TSC-related epilepsy.</p> <p align="justify">“We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the opportunity to http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html Tue, 05 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html <p align="justify">AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company’s clinical development program evaluating simufilam in TSC-related epilepsy.</p> <p align="justify">“We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the opportunity to http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html Tue, 05 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html <p align="justify">AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company’s clinical development program evaluating simufilam in TSC-related epilepsy.</p> <p align="justify">“We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the opportunity to http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html Tue, 05 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344 http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html <p align="justify">AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company’s clinical development program evaluating simufilam in TSC-related epilepsy.</p> <p align="justify">“We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the opportunity to http://www.streetinsider.com/Press+Releases/Filana+Therapeutics+Presents+TSC-Related+Epilepsy+Program+at+Eilat+XVIII/26430164.html Tue, 05 May 2026 08:00:00 -0400 A.06142904 A.06822034 FLNA O.00073827 O.06078381 O.20026344